证券日报网讯艾德生物（300685）10月16日在互动平台回答投资者提问时表示，股东的减持行为系其根 据自身资金需求作出的独立决策，公司会严格按照监管规定履行信息披露义务。公司管理层始终致力于 夯实主营业务的核心竞争力，通过持续加大研发投入、深化国内院内市场布局；加速国际化拓展进程； 扩大与药企的战略合作等方式，全力推动公司实现可持续、高质量的盈利式增长。同时，公司将持续加 强与资本市场的沟通。 ...

Core Viewpoint - The company is focused on maintaining a stable profit distribution policy while considering future dividend plans based on various factors such as business performance and regulatory requirements [1] Group 1: Company Performance and Strategy - As of October 14, 2025, the company's stock price closed at 22.31 yuan, down 1.2%, with a turnover rate of 1.57% and a trading volume of 61,100 shares, amounting to a transaction value of 137 million yuan [1] - The company has received approval for its companion diagnostic products to be used with Merck's MET inhibitors in the Chinese and Japanese markets, indicating a strategic partnership with a major pharmaceutical player [1] - The company emphasizes the importance of investor returns and is open to suggestions regarding dividend policies, which will be evaluated by the board based on the company's development stage and financial needs [1] Group 2: Industry Context and Competitive Position - The company is positioned within a growing market for high-end medical equipment, benefiting from national policies promoting domestic production and import substitution [2] - The company has developed a comprehensive sequencing technology platform, including the Salus Pro gene sequencer, which received regulatory approval as a Class III medical device in January 2025 [2] - The collaboration with SaiLu Medical aims to leverage the strengths of both companies in sequencing technology and tumor gene detection, enhancing long-term competitiveness in the industry [2] Group 3: Market Activity - On October 14, 2025, the net inflow of funds from major investors was 941,700 yuan, while retail investors experienced a net outflow of 3,077,100 yuan, indicating varied investor sentiment [3]

艾德生物回复：您好。公司高度重视对投资者的合理回报，一直秉持稳健的利润分配政策。未来具体的 分红方案，将由董事会结合公司发展阶段、实际经营业绩、未来资金需求以及相关监管法规等因素综合 考量后提出，并提交股东会审议。感谢您对公司的宝贵建议。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，艾德生物(300685)10月14日在投资者关系平台上答复投资者关心的问题。 投资者提问：公司作为全国社保重仓持有的品种，未来是否考虑增大派息等分红方式，谢谢。 ...

13 October 2025 | 6:39PM CST Equity Research China Healthcare: 3Q25 preview: United Imaging & Lepu to lead revenue growth, Zhifei still at cycle trough Companies with higher revenue growth: We expect United Imaging to lead our coverage universe with a 44% yoy revenue growth in 3Q25. We believe the company's strong growth momentum is mainly driven by the improvement in China's hospital bidding data, which has begun to be reflected in its financial statements. We also expect Lepu to achieve rapid revenue grow ...

10月9日主力资金净流出2171.94万元；游资资金净流入617.9万元；散户资金净流入1554.04万元。 公司公告汇总第四届董事会第八次会议决议公告 证券代码：300685 证券简称：艾德生物 公告编号：2025-044 截至2025年10月9日收盘，艾德生物(300685)报收于22.96元，下跌0.17%，换手率2.39%，成交量9.32万 手，成交额2.13亿元。 当日关注点 交易信息汇总资金流向 厦门艾德生物医药科技股份有限公司第四届董事会第八次会议于2025年10月9日召开，会议应到董事7 人，实到7人，符合法定人数。会议审议通过《关于公司对外投资的议案》，表决结果为7票赞成，0票 反对，0票弃权。艾德生物与深圳赛陆医疗科技有限公司及其现有股东签署《B轮增资协议》，以现金 方式向赛陆医疗增资5,000万元，其中5.5701万元计入注册资本，其余计入资本公积金，增资完成后持有 赛陆医疗2.3810%股权。具体内容详见同日披露的对外投资公告。备查文件为本次董事会决议。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交 ...

截至2025年10月9日收盘，艾德生物（300685）报收于22.96元，较前一交易日下跌0.17%，最新总市值 为89.9亿元。该股当日开盘23.2元，最高23.23元，最低22.5元，成交额达2.13亿元，换手率为2.39%。 《第四届董事会第八次会议决议公告》 根据公司于近日发布的公告，厦门艾德生物医药科技股份有限公司第四届董事会第八次会议于2025年10 月9日召开，会议审议通过《关于公司对外投资的议案》。公告显示，艾德生物与深圳赛陆医疗科技有 限公司及其现有股东签署《B轮增资协议》，将以现金方式向赛陆医疗增资5,000万元，其中5.5701万元 计入注册资本，其余计入资本公积金。本次增资完成后，艾德生物将持有赛陆医疗2.3810%的股权。 最新公告列表 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

赛陆医疗是国家高新技术企业和国家专精特新小巨人企业，专注于开发自主知识产权的上游测序平台、 超分辨空间组学平台和固相基因芯片检测平台，实现基因组学、空间组学以及基因芯片产品的自主开发 及科研临床端转化。赛陆医疗核心技术荣获全国颠覆性技术创新大赛优秀奖、粤港澳大湾区高价值专利 培育布局大赛金奖等，并拥有已授权专利总数110余件，核心产品涵盖多款覆盖大中小通量的测序仪、 空间组学和固相芯片解决方案；其中SalusPro基因测序仪于2025年1月获批三类医疗器械注册证，该产 品采用可逆末端终止测序技术，在临床上用于对来源于人体样本的脱氧核糖核酸（DNA）和核糖核酸 （RNA）进行测序。 格隆汇10月9日丨艾德生物(300685.SZ)公布，公司与深圳赛陆医疗科技有限公司（简称"赛陆医疗""标的 公司"）及其现有股东签署了《B轮增资协议》。艾德生物以现金方式向赛陆医疗增资5,000万元，其中 5.5701万元作为赛陆医疗新增注册资本，其余部分计入赛陆医疗资本公积金，本次增资后艾德生物持有 赛陆医疗2.3810%的股权。 ...

格隆汇10月9日丨艾德生物(300685.SZ)公布，公司与深圳赛陆医疗科技有限公司（简称"赛陆医疗""标的 公司"）及其现有股东签署了《B轮增资协议》。艾德生物以现金方式向赛陆医疗增资5,000万元，其中 5.5701万元作为赛陆医疗新增注册资本，其余部分计入赛陆医疗资本公积金，本次增资后艾德生物持有 赛陆医疗2.3810%的股权。 赛陆医疗是国家高新技术企业和国家专精特新小巨人企业，专注于开发自主知识产权的上游测序平台、 超分辨空间组学平台和固相基因芯片检测平台，实现基因组学、空间组学以及基因芯片产品的自主开发 及科研临床端转化。赛陆医疗核心技术荣获全国颠覆性技术创新大赛优秀奖、粤港澳大湾区高价值专利 培育布局大赛金奖等，并拥有已授权专利总数110余件，核心产品涵盖多款覆盖大中小通量的测序仪、 空间组学和固相芯片解决方案；其中SalusPro基因测序仪于2025年1月获批三类医疗器械注册证，该产 品采用可逆末端终止测序技术，在临床上用于对来源于人体样本的脱氧核糖核酸（DNA）和核糖核酸 （RNA）进行测序。 （原标题：艾德生物(300685.SZ)：拟向赛陆医疗增资5000万元） ...

格隆汇10月9日｜艾德生物公告，10月9日，厦门艾德生物医药科技股份有限公司与深圳赛陆医疗科技有 限公司及其现有股东签署了《B轮增资协议》。艾德生物以现金方式向赛陆医疗增资5,000万元，其中 5.5701万元作为赛陆医疗新增注册资本，其余部分计入赛陆医疗资本公积金，本次增资后艾德生物持有 赛陆医疗2.3810%的股权。公司于2025年10月9日召开第四届董事会第八次会议，审议通过了《关于公 司对外投资的议案》。 ...

Core Viewpoint - The investment in Sailu Medical by Aide Biological is a strategic move to strengthen its position in the gene testing industry and enhance collaboration within the supply chain [1][2] Group 1: Investment Details - Aide Biological signed a B-round capital increase agreement with Sailu Medical, investing 50 million yuan, with 55,701 yuan allocated to the registered capital and the remainder to capital reserves [1] - Following this investment, Aide Biological holds a 2.3810% stake in Sailu Medical [1] Group 2: Industry Context - Sailu Medical operates in a technology-intensive sector with significant R&D barriers and has developed a self-controlled sequencing technology platform [1] - The company has full R&D and production capabilities for gene sequencing instruments and related consumables, with its SalusPro gene sequencer receiving national Class III medical device registration in January 2025 [1] - The national push for high-end medical equipment to be self-controlled and for import substitution presents strategic growth opportunities for domestic sequencing platform companies with core technologies [1] Group 3: Strategic Implications - The investment is a key strategic deployment for Aide Biological, aligning with the trends in the gene testing industry and enhancing supply chain collaboration [2] - The partnership will leverage Sailu Medical's core advantages in sequencing platforms and Aide Biological's expertise in tumor gene testing, creating a strong complementary effect [2] - This collaboration aims to improve the overall competitiveness of the company in the industry and promote resource integration, fostering a more self-controlled and collaborative industrial ecosystem [2] - The initiative is expected to accelerate innovation and clinical translation of cutting-edge technologies, providing more precise and accessible gene testing solutions for patients [2] - It will further solidify the company's leading position in the field of tumor precision medicine [2]